AI Article Synopsis
- Aeromonas spp. are gaining attention as human pathogens, particularly due to their ability to produce metallo-beta-lactamases, which complicates treatment with beta-lactam antibiotics.
- Current strategies to combat beta-lactamase resistance lack effective clinical inhibitors for these metallo-beta-lactamases.
- Cefotetan was found to act as a transient inactivator of metallo-beta-lactamase activity in Aeromonas spp., suggesting it may be an effective antimicrobial agent against these strains despite being a poor substrate for direct hydrolysis by the enzymes.
Article Abstract
Aeromonas spp. are increasingly being recognized as human pathogens. The presence of metallo-beta-lactamases in these organisms represents a potential problem in antimicrobial therapy. Mechanism-based inactivators of beta-lactamases are used to overcome the resistance of clinical pathogens to beta-lactam antibiotics, but no clinical useful inhibitors of the metallo-beta-lactamases are presently known. Studying the interaction between cefotetan and Aeromonas spp. producing metallo-beta-lactamase activity, we observed that cefotetan behaved as a transient inactivator for both the crude extracts of Aeromonas strains and the purified enzymes from Aeromonas hydrophila AE036 and Aeromonas schubertii MNSA20. The direct hydrolysis of cefotetan showed that it was a poor substrate for both purified enzymes. In view of the minimum inhibitory concentrations, cefotetan shows to be a useful antimicrobial agent against Aeromonas spp.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000007275 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!